Rishi’s strategy involves mitigating biology discovery risk by in-licensing programs with therapeutically validated targets and small molecule leads; consequently the management team will be able to select programs with initial pivotal proof of principle experiments in place.
Rishi will concentrate on programs that integrate complementary assets in the US and India to develop a portfolio of novel therapeutic products that address unmet medical needs.
Infectious Disease: $23 billion market for novel antibiotics that address therapeutic challenges including resistance. Animal models are highly predictive of clinical outcome, and compounds that attain success in Phase II clinical evaluation have a greater likelihood of commercial success.
